249 related articles for article (PubMed ID: 31102573)
1. Identification of Factors Affecting Tacrolimus Trough Levels in Latin American Pediatric Liver Transplant Patients.
Riva N; Woillard JB; Distefano M; Moragas M; Dip M; Halac E; Cáceres Guido P; Licciardone N; Mangano A; Bosaleh A; de Davila MT; Schaiquevich P; Imventarza O
Liver Transpl; 2019 Sep; 25(9):1397-1407. PubMed ID: 31102573
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation.
Monchaud C; de Winter BC; Knoop C; Estenne M; Reynaud-Gaubert M; Pison C; Stern M; Kessler R; Guillemain R; Marquet P; Rousseau A
Clin Pharmacokinet; 2012 Mar; 51(3):175-86. PubMed ID: 22339449
[TBL] [Abstract][Full Text] [Related]
3. Survival Time to Biopsy-Proven Acute Rejection and Tacrolimus Adverse Drug Reactions in Pediatric Liver Transplantation.
Riva N; Dip M; Halac E; Cáceres Guido P; Woillard JB; Licciardone N; Chan D; Buendía J; Borgnia D; Bosaleh A; de Davila MT; Imventarza O; Schaiquevich P
Ther Drug Monit; 2018 Aug; 40(4):401-410. PubMed ID: 29621122
[TBL] [Abstract][Full Text] [Related]
4. A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation.
Andrews LM; Hesselink DA; van Gelder T; Koch BCP; Cornelissen EAM; Brüggemann RJM; van Schaik RHN; de Wildt SN; Cransberg K; de Winter BCM
Clin Pharmacokinet; 2018 Apr; 57(4):475-489. PubMed ID: 28681225
[TBL] [Abstract][Full Text] [Related]
5. Benefits of minimizing immunosuppressive dosage according to cytochrome P450 3A5 genotype in liver transplant patients: findings from a single-center study.
Wang L; Li N; Wang MX; Lu SC
Genet Mol Res; 2015 Apr; 14(2):3191-9. PubMed ID: 25966085
[TBL] [Abstract][Full Text] [Related]
6. Differences in CYP3A genotypes of a liver transplant recipient and the donor liver graft and adjustment of tacrolimus dose.
Berger FA; Mulder MB; Ten Bosch-Dijksman W; van Schaik RHN; Coenen S; de Winter BCM
Br J Clin Pharmacol; 2019 Aug; 85(8):1852-1854. PubMed ID: 31190414
[TBL] [Abstract][Full Text] [Related]
7. Impact of CYP3A5 polymorphism on trough concentrations and outcomes of tacrolimus minimization during the early period after kidney transplantation.
Yaowakulpatana K; Vadcharavivad S; Ingsathit A; Areepium N; Kantachuvesiri S; Phakdeekitcharoen B; Sukasem C; Sra-Ium S; Sumethkul V; Kitiyakara C
Eur J Clin Pharmacol; 2016 Mar; 72(3):277-83. PubMed ID: 26635230
[TBL] [Abstract][Full Text] [Related]
8. CYP3A5 Genotype and Time to Reach Tacrolimus Therapeutic Levels in Renal Transplant Children.
Alvarez-Elías AC; García-Roca P; Velásquez-Jones L; Valverde S; Varela-Fascinetto G; Medeiros M
Transplant Proc; 2016 Mar; 48(2):631-4. PubMed ID: 27110018
[TBL] [Abstract][Full Text] [Related]
9. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic concentration achievement and allograft survival comparing usage of conventional tacrolimus doses and CYP3A5 genotype-guided doses in renal transplantation patients.
Anutrakulchai S; Pongskul C; Kritmetapak K; Limwattananon C; Vannaprasaht S
Br J Clin Pharmacol; 2019 Sep; 85(9):1964-1973. PubMed ID: 31077425
[TBL] [Abstract][Full Text] [Related]
11. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
Muller WK; Dandara C; Manning K; Mhandire D; Ensor J; Barday Z; Freercks R
S Afr Med J; 2020 Jan; 110(2):159-166. PubMed ID: 32657689
[TBL] [Abstract][Full Text] [Related]
12. Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation.
Uesugi M; Kikuchi M; Shinke H; Omura T; Yonezawa A; Matsubara K; Fujimoto Y; Okamoto S; Kaido T; Uemoto S; Masuda S
Pharmacogenet Genomics; 2014 Jul; 24(7):356-66. PubMed ID: 24911663
[TBL] [Abstract][Full Text] [Related]
13. Effects of combinational CYP3A5 6986A>G polymorphism in graft liver and native intestine on the pharmacokinetics of tacrolimus in liver transplant patients: a meta-analysis.
Buendia JA; Bramuglia G; Staatz CE
Ther Drug Monit; 2014 Aug; 36(4):442-7. PubMed ID: 24378577
[TBL] [Abstract][Full Text] [Related]
14. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
[TBL] [Abstract][Full Text] [Related]
15. The TOMATO Study (Tacrolimus Metabolization in Kidney Transplantation): Impact of the Concentration-Dose Ratio on Death-censored Graft Survival.
Jouve T; Fonrose X; Noble J; Janbon B; Fiard G; Malvezzi P; Stanke-Labesque F; Rostaing L
Transplantation; 2020 Jun; 104(6):1263-1271. PubMed ID: 31415035
[TBL] [Abstract][Full Text] [Related]
16. Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism--a prospective, randomized, controlled study.
Chen SY; Li JL; Meng FH; Wang XD; Liu T; Li J; Liu LS; Fu Q; Huang M; Wang CX
Clin Transplant; 2013; 27(3):E272-81. PubMed ID: 23432535
[TBL] [Abstract][Full Text] [Related]
17. Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers.
Tang HL; Xie HG; Yao Y; Hu YF
Pharmacogenet Genomics; 2011 Nov; 21(11):713-20. PubMed ID: 21886016
[TBL] [Abstract][Full Text] [Related]
18. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
[TBL] [Abstract][Full Text] [Related]
19. A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients.
Andrews LM; Hesselink DA; van Schaik RHN; van Gelder T; de Fijter JW; Lloberas N; Elens L; Moes DJAR; de Winter BCM
Br J Clin Pharmacol; 2019 Mar; 85(3):601-615. PubMed ID: 30552703
[TBL] [Abstract][Full Text] [Related]
20. Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients.
Kim IW; Moon YJ; Ji E; Kim KI; Han N; Kim SJ; Shin WG; Ha J; Yoon JH; Lee HS; Oh JM
Eur J Clin Pharmacol; 2012 May; 68(5):657-69. PubMed ID: 22183771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
